BCL2

Summary: BCL2 can promote apoptosis after cleavage or conformational conversion, while its predominant intact-protein role is anti-apoptotic.

Reason: The former categorical rejection overlooked conditional target activity. PMID:18835031 demonstrates BCL2-dependent death and a biochemical mechanism: exposed BCL2 BH3 neutralizes BCLXL, thereby permitting Bax-dependent permeabilization. The converted protein is not merely an inactive substrate, nor does this experiment show direct Bax activation by converted BCL2. Caspase cleavage and Nur77 conversion are also reported in PMID:9395403 and PMID:14980220. PAINT places both positive and negative apoptosis regulation at PTN000135648 in PTHR11256; no target-specific loss is established. Retain the positive role as contextual. The focused OpenScientist report independently concurs on cleavage and Nur77-dependent conversion; its general Bax-like wording does not override the experimentally resolved BCLXL-neutralization mechanism. Physiological prevalence remains a follow-up question, not a reason to reject demonstrated capacity.

Summary: BCL2 controls the apoptotic response to withdrawal of survival ligands.

Reason: GO:0097192 begins with withdrawal of ligand from a cell-surface receptor; it is compatible with downstream mitochondrial control. PMID:8358790 assays cytokine-deprivation death and its inhibition by BCL2, and PMID:1373874 demonstrates protection after IL-7 withdrawal. The IBD at PTN000135648 therefore need not be replaced by an intrinsic-pathway term merely because BCL2 acts at mitochondria.

Summary: BCL2 localizes to the mitochondrial outer membrane via its C-terminal transmembrane helix. This is a well-established localization critical for its anti-apoptotic function.

Reason: Multiple experimental studies confirm BCL2 localization to the OMM (PMID:9027314, PMID:21358617, PMID:2250705). UniProt annotation confirms this localization with experimental evidence. The IBA annotation is phylogenetically sound.

Summary: BCL2 controls mitochondrial apoptotic signaling triggered by DNA damage.

Reason: Retain the broad IBD at PTN000135648. BCL2 inhibition of the mitochondrial pathway is compatible with participation in this signaling response; the p53-specific negative-regulation term is useful additional specificity but does not invalidate the existing broader annotation. PMID:12667443 and PMID:16443602 establish target interaction with mitochondrial p53.

Summary: Human BCL2 has demonstrated membrane-channel capacity in reconstituted systems.

Reason: PMID:9219694 reports BCL2-dependent liposome permeabilization at acidic pH and Bax-channel inhibition at physiological pH. Independently, full-text PMID:9144199 records discrete channels from purified human BCL2(1–218), lacking its terminal anchor, at pH 7.4; acidic conditions increase membrane insertion. Thus channel capacity and resulting transmembrane ion movement cannot be rejected as absent or exclusively acidic. Their native physiological contribution remains unresolved and distinct from established channel inhibition. The channel IBD at PTN000135648 includes experimental human P10415 evidence, which is legitimate target grounding rather than circular transfer. The focused OpenScientist report concurs on channel capacity, but its acidic-only permeabilization summary describes the larger carboxyfluorescein readout and must not be generalized to small-ion conductance. Transmembrane transport does not require bulk solute movement or a conventional transporter architecture.

Summary: BCL2 can promote cytochrome-c release in a converted proapoptotic state, although ordinary intact BCL2 inhibits release.

Reason: The prior global replacement assumed that BCL2 can only inhibit this process. PMID:18835031 shows that converted BCL2 exposes its BH3 domain and neutralizes BCLXL, facilitating Bax-dependent permeabilization; PMID:14980220 reports Nur77-dependent conversion and cytochrome-c release. This is active regulatory work, not evidence that BCL2 constitutively forms the cytochrome-c pore. Preserve the inherited process as contextual while focused adjudication evaluates the exact release-versus-regulation scope. The original PAINT source is PTN000135648.

Summary: Human BCL2 has demonstrated membrane-channel capacity in reconstituted systems.

Reason: PMID:9219694 reports BCL2-dependent liposome permeabilization at acidic pH and Bax-channel inhibition at physiological pH. Independently, full-text PMID:9144199 records discrete channels from purified human BCL2(1–218), lacking its terminal anchor, at pH 7.4; acidic conditions increase membrane insertion. Thus channel capacity and resulting transmembrane ion movement cannot be rejected as absent or exclusively acidic. Their native physiological contribution remains unresolved and distinct from established channel inhibition. The channel IBD at PTN000135648 includes experimental human P10415 evidence, which is legitimate target grounding rather than circular transfer. The focused OpenScientist report concurs on channel capacity, but its acidic-only permeabilization summary describes the larger carboxyfluorescein readout and must not be generalized to small-ion conductance. Transmembrane transport does not require bulk solute movement or a conventional transporter architecture.

Summary: BCL2 is found in the cytoplasm, though primarily membrane-associated at the OMM and ER. This is a broad but acceptable localization term.

Reason: BCL2 is present in the cytoplasm, particularly associated with intracellular membranes. Multiple studies confirm cytoplasmic distribution (PMID:7546744, PMID:11530860).

Summary: BCL2 localizes to the mitochondrial outer membrane. This IEA annotation is consistent with experimental evidence and the IBA annotation above.

Reason: Well-supported by experimental evidence (PMID:9027314, PMID:2250705, PMID:21358617). UniProt subcellular location annotation confirms this with multiple PubMed references.

Summary: BCL2 also localizes to the ER membrane where it interacts with BECN1 and IP3 receptors, modulating autophagy and calcium homeostasis.

Reason: PMID:21358617 demonstrates BCL2 localization at the ER membrane and interactions with AMBRA1 and BECN1 at this location. UniProt confirms ER localization with experimental evidence.

Summary: BCL2 inhibits autophagy through interactions with BECN1 and AMBRA1.

Reason: This is demonstrated inhibitory work within autophagy regulation, not a reason to reject the annotation as crosstalk. Full-text PMID:21358617 combines interaction/domain experiments with LC3 conversion and chloroquine flux controls: mitochondrial BCL2 inhibits AMBRA1-driven autophagosome formation, while the AMBRA1 fragment unable to bind BCL2 escapes that inhibition. PMID:17446862 establishes BH3-dependent BECN1 interaction. These functions coexist with apoptosis regulation.

Summary: BCL2 is involved in the apoptotic process as a key negative regulator. This general term is acceptable though less informative than more specific terms.

Reason: BCL2 is definitively involved in the apoptotic process. Multiple experimental studies confirm this (PMID:9027314, PMID:9219694). The term is broad but accurate.

Summary: BCL2 is a membrane protein with a C-terminal transmembrane anchor. This is a very general term but accurate.

Reason: BCL2 is an integral membrane protein. More specific membrane terms (OMM, ER membrane) are more informative, but this general term is not incorrect.

Summary: BCL2 has been detected at the nuclear envelope, though this is not considered its primary site of action.

Reason: PMID:2250705 and PMID:8402648 report BCL2 localization to the nuclear membrane. UniProt confirms this localization. While not the primary site of function, it is a validated localization.

Summary: BCL2 directly regulates apoptotic signaling through inhibitory protein interactions.

Reason: The broader signaling/apoptosis regulation term accurately encompasses BCL2 restraint of mitochondrial permeabilization and downstream caspase activation. Coexistence with more specific negative-regulation terms does not make this biological role false or require replacement.

Summary: BCL2 negatively regulates apoptosis. This is a core function annotation that accurately describes BCL2's primary biological role.

Reason: This is BCL2's core evolved function. Multiple experimental studies demonstrate BCL2 prevents apoptosis (PMID:9027314, PMID:1373874, PMID:7650367, PMID:7772249).

Summary: BCL2 forms complexes with other Bcl-2 family members including homodimers and heterodimers with BAX, BAD, BAK, and BCL-XL.

Reason: PMID:9111042 demonstrates BCL2 forms homodimers and heterodimers with other family members through the BH3-binding groove. This is well-established.

Summary: BCL2 directly regulates apoptotic signaling through inhibitory protein interactions.

Reason: The broader signaling/apoptosis regulation term accurately encompasses BCL2 restraint of mitochondrial permeabilization and downstream caspase activation. Coexistence with more specific negative-regulation terms does not make this biological role false or require replacement.

Summary: BCL2 directly regulates apoptotic signaling through inhibitory protein interactions.

Reason: The broader signaling/apoptosis regulation term accurately encompasses BCL2 restraint of mitochondrial permeabilization and downstream caspase activation. Coexistence with more specific negative-regulation terms does not make this biological role false or require replacement.

Summary: Generic protein binding is not informative for BCL2's specific molecular function. BCL2 binds BH3-domain containing proteins through its hydrophobic groove.

Reason: BCL2's protein binding is specifically through BH3 domain interactions. The term GO:0051434 (BH3 domain binding) would be more informative and accurate.

Proposed replacements: BH3 domain binding

Summary: BCL2 interacts with the transcription factor p53 at mitochondria.

Reason: PMID:12667443 reports a p53/BCL2 complex; PMID:16443602 maps the BCL2-binding surface to the p53 DNA-binding domain by NMR and measures binding. This is transcription-factor binding, not BH3-domain binding, and does not assert that BCL2 itself binds DNA.

Proposed replacements: DNA-binding transcription factor binding

Summary: The cited study reports BCL2 interaction evidence involving SIVA and its amphipathic SAH region.

Reason: Preserve the interaction finding from PMID:14739602, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: BCL2 binds protein phosphatase 2A, which regulates BCL2 phosphorylation.

Reason: PMID:15225643 directly characterizes the PP2A interaction. Replace generic binding with the already supported PP2A-specific molecular function; do not infer that every BCL2 partner presents a BH3 domain.

Proposed replacements: protein phosphatase 2A binding

Summary: This study on BH3-only protein binding to BCL2 family members directly supports BH3 domain binding as the specific function.

Reason: The reference specifically studies BH3 ligand binding to pro-survival BCL2 proteins. GO:0051434 (BH3 domain binding) is the appropriate specific term.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving FKBP38 and the unstructured BCL2 loop.

Reason: Preserve the interaction finding from PMID:15733859, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: Generic protein binding annotation.

Reason: BCL2 protein binding is primarily through BH3 domain interactions.

Proposed replacements: BH3 domain binding

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:17074758 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: Study on BH3 ligands engaging BCL2 homologs - directly demonstrates BH3 domain binding function.

Reason: The study title "Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs" directly supports BH3 domain binding annotation.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving NLRP1.

Reason: Preserve the interaction finding from PMID:17418785, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:17446862 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: Generic protein binding annotation.

Reason: BCL2 protein binding is primarily through BH3 domain interactions.

Proposed replacements: BH3 domain binding

Summary: Generic protein binding annotation from BH3 profiling study.

Reason: BH3 profiling study directly supports BH3 domain binding annotation.

Proposed replacements: BH3 domain binding

Summary: BCL2 recognizes mapped sites in the ankyrin/SH3 region of ASPP2.

Reason: Full-text PMID:18719108 maps BCL2 binding to ASPP2 peptides, including residues 1065–1082 at the beginning of its SH3 domain, and measures peptide affinities. This supports SH3-domain binding as an informative interaction specificity. The BCL2 BH4 surface participates in the interaction; ASPP2 is not established here as a BH3-only ligand.

Proposed replacements: SH3 domain binding

Summary: Nur77-derived protein fragments and peptides bind the BCL2 regulatory loop.

Reason: Full-text PMID:18835031 demonstrates binding of Nur77 protein fragments including a DNA-binding-domain deletion mutant, and competition by NuBCP-9. Nur77 is a transcription factor even though this mitochondrial interaction does not use its DNA-binding domain. Replace generic binding with transcription-factor binding, while documenting separately that the interaction changes BCL2 conformation.

Proposed replacements: DNA-binding transcription factor binding

Summary: Generic protein binding annotation.

Reason: BCL2 protein binding is primarily through BH3 domain interactions.

Proposed replacements: BH3 domain binding

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:19050071 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: Generic protein binding annotation.

Reason: BCL2 protein binding is primarily through BH3 domain interactions.

Proposed replacements: BH3 domain binding

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:19180116 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving NLRP1 and the BCL2 loop.

Reason: Preserve the interaction finding from PMID:19223583, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The MDM4 study demonstrates a mitochondrial p53/BCL2 interaction in addition to MDM4/BCL2 association.

Reason: PMID:19521340 describes MDM4-dependent association of p53Ser46P with BCL2. Transcription-factor binding is a supported informative replacement for this generic interaction annotation. The study does not justify labeling MDM4 itself a BH3 ligand.

Proposed replacements: DNA-binding transcription factor binding

Summary: BCL2 binding to IP3 receptors inhibits channel opening and apoptotic calcium signals.

Reason: PMID:19706527 establishes inhibitory function for the BCL2 BH4/IP3-receptor interaction, supporting channel inhibitor activity. The interacting domain is not a BH3 domain and the assay measures regulation of another channel, rather than calcium transport through BCL2 itself.

Proposed replacements: channel inhibitor activity

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:19959994 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving NAF-1/CISD2.

Reason: Preserve the interaction finding from PMID:20010695, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:21139567 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:21199865 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: The cited study reports BCL2 interaction evidence involving AMBRA1.

Reason: Preserve the interaction finding from PMID:21358617, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:21454712 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:21458670 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: Generic protein binding annotation.

Reason: More specific MF term available.

Proposed replacements: BH3 domain binding

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:23541952 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:23845444 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: Human and mouse Beclin 2 co-immunoprecipitate with BCL2.

Reason: Full-text PMID:23954414 directly reports Beclin 2/BCL2 association, whose starvation response differs from Beclin 1. The report does not map this association to a defined Beclin 2 BH3 interface. Remove generic binding as uninformative rather than infer an untested domain-specific replacement or reject the interaction.

Summary: Generic protein binding annotation.

Reason: More specific MF term available.

Proposed replacements: BH3 domain binding

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:24472739 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: BDA-366 changes BCL2 interactions with BAX and BIM in the reported cellular assays.

Reason: Full-text PMID:26004684 Figure 2G measures increased BCL2/BAX and decreased BCL2/BIM association after treatment. The molecular-function replacement describes documented BCL2 heteromeric binding rather than the small-molecule binding itself or a generic interaction. Conditional proapoptotic conversion is evaluated separately.

Proposed replacements: protein heterodimerization activity

Summary: Generic protein binding - PUMA/BCL2 interaction.

Reason: PUMA is a BH3-only protein, supporting BH3 domain binding annotation.

Proposed replacements: BH3 domain binding

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:29749471 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: Study on BCL2-BECN1 interaction in autophagy and longevity.

Reason: Remove the generic protein-binding annotation because it does not describe a specific molecular function. The interaction evidence and source attribution are retained; this curation action does not assert that the reported association is false. The inspected evidence does not justify an informative replacement function for this particular row.

Summary: The cited study reports BCL2 interaction evidence involving the HuRI interaction network.

Reason: Preserve the interaction finding from PMID:32296183, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving the neurodegeneration interaction network.

Reason: Preserve the interaction finding from PMID:32814053, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving the BioPlex interaction network.

Reason: Preserve the interaction finding from PMID:33961781, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving BAP31.

Reason: Preserve the interaction finding from PMID:9334338, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: Study on BAD dimerization properties and BH3 domain binding to BCL2.

Reason: This study directly characterizes BH3 domain binding: "Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins."

Proposed replacements: BH3 domain binding

Summary: Study on BH4 domain required for CED-4 interaction and anti-apoptotic activity.

Reason: Remove the generic protein-binding annotation because it does not describe a specific molecular function. The interaction evidence and source attribution are retained; this curation action does not assert that the reported association is false. The inspected evidence does not justify an informative replacement function for this particular row.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:9973195 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: BCL2 fragments interact with other BCL2 sequences in the conformational-mapping experiments.

Reason: Full-text PMID:18835031 Figure 7 shows association between the BCL2 N-terminal BH4-containing region and a BH4-deleted BCL2 construct. This supports binding between products of the same gene while distinguishing fragment mapping from proof that all intact molecules are stable homodimers.

Summary: BCL2 homodimerization is retained after BH4 deletion in the cited assay.

Reason: The direct homodimerization observation supports identical protein binding. Domain deletions used in this experiment do not establish that the interaction is restricted to a unique physiological isoform.

Summary: BCL2 can promote cytochrome-c release in a converted proapoptotic state, although ordinary intact BCL2 inhibits release.

Reason: The prior global replacement assumed that BCL2 can only inhibit this process. PMID:18835031 shows that converted BCL2 exposes its BH3 domain and neutralizes BCLXL, facilitating Bax-dependent permeabilization; PMID:14980220 reports Nur77-dependent conversion and cytochrome-c release. This is active regulatory work, not evidence that BCL2 constitutively forms the cytochrome-c pore. Preserve the inherited process as contextual while focused adjudication evaluates the exact release-versus-regulation scope. The original PAINT source is PTN000135648.

Summary: BCL2 has been detected in the nucleus in some studies, though this is not its primary localization.

Reason: Some studies report nuclear localization (PMID:7546744, PMID:7896880), though the primary localization is at OMM and ER membranes.

Summary: BCL2 localizes to mitochondria, specifically the outer membrane.

Reason: Well-established localization supported by multiple experimental studies.

Summary: BCL2 localizes to the ER, specifically the ER membrane.

Reason: Supported by experimental evidence (PMID:21358617, PMID:8402648).

Summary: BCL2 can occur in the cytosol as well as in membrane compartments.

Reason: The Ensembl orthology transfer is from mouse P10417. PMID:12617961 identifies endogenous calcineurin/BCL2 complexes in rat and mouse brain cytosol as well as mitochondrial, nuclear and microsomal fractions. A terminal membrane anchor and prominent membrane localization do not establish cytosolic exclusion. Retain the nonexclusive compartment inference without asserting that the soluble pool predominates.

Summary: BCL2 can increase net cell population expansion by promoting survival in a growth-factor-dependent context.

Reason: Mouse P10417 is the recorded orthology source. Independent human-BCL2 expression experiments in PMID:1373874 show a context-dependent net proliferative advantage in pre-B cells. Survival control is functional regulatory work and does not require BCL2 to be a cell-cycle enzyme. This broad population-level annotation is retained as non-core; it does not establish acceleration of the division cycle.

Summary: BCL2 inhibits autophagy through interactions with BECN1 and AMBRA1.

Reason: This is demonstrated inhibitory work within autophagy regulation, not a reason to reject the annotation as crosstalk. Full-text PMID:21358617 combines interaction/domain experiments with LC3 conversion and chloroquine flux controls: mitochondrial BCL2 inhibits AMBRA1-driven autophagosome formation, while the AMBRA1 fragment unable to bind BCL2 escapes that inhibition. PMID:17446862 establishes BH3-dependent BECN1 interaction. These functions coexist with apoptosis regulation.

Summary: BCL2 inhibits autophagy through interactions with BECN1 and AMBRA1.

Reason: This is demonstrated inhibitory work within autophagy regulation, not a reason to reject the annotation as crosstalk. Full-text PMID:21358617 combines interaction/domain experiments with LC3 conversion and chloroquine flux controls: mitochondrial BCL2 inhibits AMBRA1-driven autophagosome formation, while the AMBRA1 fragment unable to bind BCL2 escapes that inhibition. PMID:17446862 establishes BH3-dependent BECN1 interaction. These functions coexist with apoptosis regulation.

Summary: BCL2 interacts with protein phosphatases including PP2A, which regulates BCL2 phosphorylation status.

Reason: BCL2 is regulated by phosphorylation/dephosphorylation at Ser-70. Interaction with phosphatases is documented but is regulatory, not a core molecular function.

Summary: BCL2-dependent cell survival contributes to hair-follicle development and maintenance.

Reason: Retain the mouse P10417 orthology transfer as a tissue-specific developmental role. Mouse loss-of-function evidence includes abnormalities emerging with the second follicle cycle (PMID:8402909), and melanocyte-survival work is supported by PMID:12086670. Such developmental consequences need not be core to be valid; the term does not assert that BCL2 catalyzes pigment synthesis. The broad morphogenesis inference is not resolved to a specific follicular cell type by the abstract alone.

Summary: BCL2 localizes to the mitochondrial membrane, specifically the outer membrane.

Reason: Supported by experimental evidence. More specific term (OMM) is preferred but this is accurate.

Summary: The specific myelin-sheath localization requires the original microscopy evidence.

Reason: The orthology source is mouse P10417. PMID:7953633 reports BCL2 immunoreactivity in cultured oligodendrocytes as well as neurons and astrocytes, but the available abstract does not resolve sheath versus cell-body localization. Full-text retrieval did not supply the required images. Neither expression in a myelinating cell nor predominant mitochondrial/ER localization settles the narrower location.

Summary: BCL2 supports pigmentation by preserving melanocyte survival.

Reason: PMID:12086670 connects BCL2 loss to melanocyte loss and genetic interaction with Mitf, and BCL2 overexpression rescues apoptosis after MITF disruption. BCL2 executes survival control in the pigment-cell lineage; this is a valid developmental contribution without making it a pigment-synthesis enzyme. Retain the P10417 orthology inference as non-core.

Summary: BCL2-dependent survival can support productive HSV-2 replication.

Reason: PMID:16950491 directly tests BCL2 overexpression in human U937 cells and observes increased productive infection together with protection against apoptosis. Host survival is a mechanism of regulation in this context, not a reason to reject it for lacking an evolved viral role. Retain the broad regulatory term while distinguishing it from direct viral nucleic-acid synthesis.

Summary: BCL2 regulates mitochondrial membrane permeability by preventing MOMP. This is a core function.

Reason: This accurately describes BCL2's core function in preventing MOMP and maintaining mitochondrial membrane integrity.

Summary: BCL2 interacts with PP2A which regulates its phosphorylation status.

Reason: PP2A regulates BCL2 phosphorylation at Ser-70. This is a regulatory interaction, not a core molecular function of BCL2.

Summary: BCL2 helps maintain mitochondrial membrane potential by preventing MOMP.

Reason: By preventing MOMP, BCL2 helps maintain mitochondrial membrane potential. This is related to its core anti-apoptotic function.

Summary: The broad adaptor inference has plausible calcineurin-targeting support but needs source-specific adjudication.

Reason: The recorded Ensembl source is mouse P10417. PMID:12617961 reports BCL2/calcineurin complexes and reduced calcineurin/IP3-receptor association in Bcl2-null brain, suggesting substrate targeting. This is compatible with adaptor function but does not by itself resolve a simultaneous ternary assembly. The former human HBx citation (PMID:26858413) demonstrates a binary BH3 interaction and is not evidence for bringing two other partners together. Preserve uncertainty about the broad transferred activity rather than infer its absence from that one binary assay.

Summary: BCL2 localizes to mitochondria based on immunofluorescence data.

Reason: Well-supported localization based on direct experimental observation.

Summary: BCL2 can promote apoptosis after cleavage or conformational conversion, while its predominant intact-protein role is anti-apoptotic.

Reason: The former categorical rejection overlooked conditional target activity. PMID:18835031 demonstrates BCL2-dependent death and a biochemical mechanism: exposed BCL2 BH3 neutralizes BCLXL, thereby permitting Bax-dependent permeabilization. The converted protein is not merely an inactive substrate, nor does this experiment show direct Bax activation by converted BCL2. Caspase cleavage and Nur77 conversion are also reported in PMID:9395403 and PMID:14980220. PAINT places both positive and negative apoptosis regulation at PTN000135648 in PTHR11256; no target-specific loss is established. Retain the positive role as contextual. The focused OpenScientist report independently concurs on cleavage and Nur77-dependent conversion; its general Bax-like wording does not override the experimentally resolved BCLXL-neutralization mechanism. Physiological prevalence remains a follow-up question, not a reason to reject demonstrated capacity.

Summary: BCL2 prevents apoptosis by blocking cytochrome c release. This is a core function with strong experimental support.

Reason: PMID:9027314 provides direct evidence that BCL2 blocks cytochrome c release and prevents apoptosis initiation.

Summary: Mitochondrial proteomics study confirming BCL2 localization.

Reason: High-throughput proteomics supporting mitochondrial localization.

Summary: The HBx structural study demonstrates recognition of a BH3-like helix by BCL2.

Reason: Full-text PMID:26858413 reports binary HBx/BCL2 binding, a 2.1-angstrom structure and interface mutants, rather than a BCL2 molecule assembling two other partners. Replace the event-specific adaptor interpretation with BH3 domain binding. The weak HBx affinity is measured capacity and does not negate the interaction.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving ARTS/XIAP-dependent BCL2 degradation.

Reason: Preserve the interaction finding from PMID:29020630, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: Direct experimental evidence for BCL2 localization at OMM.

Reason: PMID:21358617 provides direct evidence: "AMBRA1 binds preferentially the mitochondrial pool of the antiapoptotic factor BCL-2"

Summary: Direct experimental evidence for BCL2 localization at ER membrane.

Reason: PMID:21358617 demonstrates ER-BCL-2 localization and interaction with AMBRA1.

Summary: BCL2 inhibits autophagy through interactions with BECN1 and AMBRA1.

Reason: This is demonstrated inhibitory work within autophagy regulation, not a reason to reject the annotation as crosstalk. Full-text PMID:21358617 combines interaction/domain experiments with LC3 conversion and chloroquine flux controls: mitochondrial BCL2 inhibits AMBRA1-driven autophagosome formation, while the AMBRA1 fragment unable to bind BCL2 escapes that inhibition. PMID:17446862 establishes BH3-dependent BECN1 interaction. These functions coexist with apoptosis regulation.

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:25609812 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving BAP31-associated membrane complexes.

Reason: Preserve the interaction finding from PMID:31206022, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving the coronavirus 7a protein.

Reason: Preserve the interaction finding from PMID:17428862, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: Study demonstrating BCL2 homodimerization through the same binding site as heterodimerization.

Reason: PMID:9111042 directly demonstrates: "Bcl-2 forms protein-protein homodimers with itself and heterodimers with Bax"

Summary: Study showing p53 binding to BCL2 at mitochondria inducing permeabilization.

Reason: p53-BCL2 interaction at mitochondria is documented but represents a specific regulatory interaction rather than core BCL2 function.

Summary: Generic protein binding annotation.

Reason: More specific MF term available.

Proposed replacements: BH3 domain binding

Summary: BCL2 expression restores net cell growth in the reported melanoma assay.

Reason: Full-text PMID:28280358 uses a CCK-8 readout over 12–48 hours and separately measures Annexin-positive apoptosis. Figure 4 reports rescue by a BCL2 expression construct. This supports contextual regulation of net population expansion, while the assay does not distinguish increased division rate from reduced death. The annotation should not be rejected solely because BCL2 supplies survival control rather than a cell-cycle catalytic step.

Summary: BCL2 negatively regulates apoptosis - core function.

Reason: Core function with genetic interaction evidence.

Summary: Generic protein binding annotation.

Reason: More specific MF term available.

Proposed replacements: BH3 domain binding

Summary: BCL2 negatively regulates the intrinsic apoptotic pathway in response to DNA damage. This is a core function.

Reason: This specific term accurately captures BCL2's role in blocking the DNA damage-induced intrinsic apoptotic pathway.

Summary: BCL2 forms a complex with FKBP38 through its flexible loop.

Reason: PMID:15733859 supports this broad complex annotation through the named non-family partner. The previous explanation about BCL2-family homo/heterodimers did not describe the cited experiment.

Summary: BCL2 negatively regulates apoptosis - core function.

Reason: Direct experimental evidence supporting core function.

Summary: BCL2 negatively regulates apoptosis - core function.

Reason: Mutant phenotype evidence supporting core function.

Summary: The cited study reports BCL2 interaction evidence involving BAX inhibitor-1.

Reason: Preserve the interaction finding from PMID:9660918, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: BCL2 negatively regulates apoptosis - genetic interaction evidence.

Reason: Core function with genetic interaction support.

Summary: This PMID (36599) appears to be incorrectly cited - it refers to an unrelated study on Streptococcus pneumoniae antibiotic resistance.

Reason: The PMID reference appears incorrect. Cannot validate this annotation without access to the correct publication.

Summary: BCL2 is involved in the apoptotic process as a regulator. The study demonstrates BCL2 regulates apoptosis through ER calcium flux control.

Reason: PMID:8022822 provides evidence for BCL2's role in apoptosis regulation through calcium signaling.

Summary: The cited study reports BCL2 interaction evidence involving MAP-1.

Reason: Preserve the interaction finding from PMID:11060313, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving FBXO10.

Reason: Preserve the interaction finding from PMID:23431138, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: BCL2 modulates ER calcium homeostasis through IP3 receptor interactions.

Reason: BCL2's role in ER calcium regulation is documented but represents a secondary function related to its membrane localization and BH4 domain interactions with IP3 receptors.

Summary: BCL2 negatively regulates the intrinsic apoptotic signaling pathway. This is a core function.

Reason: This term accurately captures BCL2's primary function in blocking the intrinsic (mitochondrial) apoptotic pathway.

Summary: BCL2 inhibits BAX channel-forming activity. This is a key mechanistic aspect of its anti-apoptotic function.

Reason: PMID:9219694 directly demonstrates: "At physiological pH, release [by Bax] could be blocked by Bcl-2." BCL2 inhibits BAX pore formation.

Summary: BCL2 heterodimerizes with BAX to regulate apoptosis. The extrinsic pathway annotation may be overly specific as BCL2 primarily functions in the intrinsic pathway.

Reason: BCL2 can influence the extrinsic pathway through crosstalk at the mitochondrial level, but its primary function is in the intrinsic pathway.

Summary: BCL2 may influence extrinsic apoptotic signaling through crosstalk, but this is not its primary pathway.

Reason: BCL2's primary function is in the intrinsic pathway. Its influence on extrinsic signaling occurs through mitochondrial crosstalk.

Summary: Reactome pathway annotation for BCL2 sequestration of tBID at OMM.

Reason: Well-supported localization from curated pathway database.

Summary: Reactome pathway annotation for BAD displacing tBID from BCL2.

Reason: Well-supported localization from curated pathway database.

Summary: Reactome pathway annotation for BH3-only proteins inactivating BCL2.

Reason: Well-supported localization from curated pathway database.

Summary: Reactome pathway annotation for BCL2 expression.

Reason: Pathway database annotation.

Summary: Reactome pathway annotation for BCL2 binding NLRP1.

Reason: Well-supported localization.

Summary: Reactome pathway annotation for estrogen-responsive BCL2 expression.

Reason: Pathway database annotation.

Summary: Reactome pathway annotation for BCL2 expression downstream of ESR1.

Reason: Pathway database annotation.

Summary: Reactome pathway annotation for BCL2 binding antagonists.

Reason: Well-supported localization.

Summary: Reactome pathway annotation for NFE2L2-dependent BCL2 expression.

Reason: Pathway database annotation.

Summary: Reactome pathway annotation for MITF-dependent BCL2 expression.

Reason: Pathway database annotation.

Summary: Anoikis is a form of apoptosis triggered by loss of cell attachment. BCL2's anti-apoptotic function extends to preventing anoikis.

Reason: BCL2 can prevent anoikis through its general anti-apoptotic function. This is a specific context of apoptosis regulation rather than a distinct evolved function.

Summary: BCL2 inhibits autophagy through interactions with BECN1 and AMBRA1.

Reason: This is demonstrated inhibitory work within autophagy regulation, not a reason to reject the annotation as crosstalk. Full-text PMID:21358617 combines interaction/domain experiments with LC3 conversion and chloroquine flux controls: mitochondrial BCL2 inhibits AMBRA1-driven autophagosome formation, while the AMBRA1 fragment unable to bind BCL2 escapes that inhibition. PMID:17446862 establishes BH3-dependent BECN1 interaction. These functions coexist with apoptosis regulation.

Summary: BCL2 negatively regulates apoptosis - core function.

Reason: Core function with mutant phenotype evidence.

Summary: The cited study reports BCL2 interaction evidence involving PHD3.

Reason: Preserve the interaction finding from PMID:20849813, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving G0S2.

Reason: Preserve the interaction finding from PMID:19706769, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: BCL2 negatively regulates apoptotic signaling - core function.

Reason: Core function with experimental evidence.

Summary: Study on Parkin-mediated BCL2 mono-ubiquitination in autophagy regulation.

Reason: BCL2 is a substrate for ubiquitin ligases including Parkin, but this represents post-translational regulation of BCL2 rather than its core molecular function.

Summary: Direct experimental evidence for BCL2 OMM localization.

Reason: Well-supported localization.

Summary: Direct experimental evidence for BCL2 ER localization.

Reason: Well-supported localization.

Summary: Direct experimental evidence for BCL2 nuclear membrane localization.

Reason: Nuclear envelope localization is documented but is not the primary site of BCL2 function.

Summary: Human BCL2 has demonstrated membrane-channel capacity in reconstituted systems.

Reason: PMID:9219694 reports BCL2-dependent liposome permeabilization at acidic pH and Bax-channel inhibition at physiological pH. Independently, full-text PMID:9144199 records discrete channels from purified human BCL2(1–218), lacking its terminal anchor, at pH 7.4; acidic conditions increase membrane insertion. Thus channel capacity and resulting transmembrane ion movement cannot be rejected as absent or exclusively acidic. Their native physiological contribution remains unresolved and distinct from established channel inhibition. The channel IBD at PTN000135648 includes experimental human P10415 evidence, which is legitimate target grounding rather than circular transfer. The focused OpenScientist report concurs on channel capacity, but its acidic-only permeabilization summary describes the larger carboxyfluorescein readout and must not be generalized to small-ion conductance. Transmembrane transport does not require bulk solute movement or a conventional transporter architecture.

Summary: BCL2 negatively regulates apoptosis by inhibiting BAX pore formation.

Reason: PMID:9219694 demonstrates BCL2 blocks BAX-mediated membrane permeabilization, supporting its anti-apoptotic function.

Summary: BCL2 channel capacity is established, but the oligomeric pore-complex assignment remains unresolved.

Reason: GO:0046930 requires a protein complex. PMID:9219694 establishes BCL2-dependent membrane permeabilization; PMID:9144199 documents discrete channels but explicitly leaves monomeric versus dimeric channel formation open. Channel capacity should therefore be retained independently of this structural-complex question, which the focused OpenScientist report also does not settle. Its channel/pore wording supplies no additional demonstration of multimeric complex assembly. Retain UNDECIDED pending structural or biochemical assembly evidence rather than treating activity alone as a cellular-component result.

Summary: BCL2 is involved in cellular response to DNA damage through its anti-apoptotic function.

Reason: BCL2's role in DNA damage response is through its anti-apoptotic function, not a direct role in DNA repair or damage sensing.

Summary: The source-specific process assignment cannot be fully resolved from the retrieved CLL study.

Reason: PMID:17875758 includes BCL2 expression differences and pathway analysis in CD38-defined chronic lymphocytic leukemia, but retrieved full-text portions do not establish the precise BCL2 perturbation or signaling experiment underlying this annotation. HEM1 intervention and pathway-category membership cannot simply be assigned to BCL2. The complete relevant assay coverage was not obtained; use uncertainty rather than claim that survival control excludes participation in this process.

Summary: The source-specific process assignment cannot be fully resolved from the retrieved CLL study.

Reason: PMID:17875758 includes BCL2 expression differences and pathway analysis in CD38-defined chronic lymphocytic leukemia, but retrieved full-text portions do not establish the precise BCL2 perturbation or signaling experiment underlying this annotation. HEM1 intervention and pathway-category membership cannot simply be assigned to BCL2. The complete relevant assay coverage was not obtained; use uncertainty rather than claim that survival control excludes participation in this process.

Summary: The source-specific process assignment cannot be fully resolved from the retrieved CLL study.

Reason: PMID:17875758 includes BCL2 expression differences and pathway analysis in CD38-defined chronic lymphocytic leukemia, but retrieved full-text portions do not establish the precise BCL2 perturbation or signaling experiment underlying this annotation. HEM1 intervention and pathway-category membership cannot simply be assigned to BCL2. The complete relevant assay coverage was not obtained; use uncertainty rather than claim that survival control excludes participation in this process.

Summary: Cellular size/growth regulation is distinct from the demonstrated calcium and survival effects.

Reason: GO:0030307 concerns cell growth, not merely population expansion. PMID:8022822 demonstrates BCL2-dependent calcium-flux and survival changes, but its available abstract does not resolve an experiment measuring the annotated growth process. Relevant full text could not be obtained. Retain uncertainty rather than turn the predominant survival role into evidence of absence.

Summary: The sequence-specific DNA-binding experiment assays MITF bound to the BCL2 promoter.

Reason: The full primary article PMID:12086670, Results and Figure 3, uses anti-MITF chromatin immunoprecipitation and anti-MITF EMSA supershifts, with wild-type versus mutant E-box competitors. BCL2 is the regulated locus and survival effector; it is not the DNA-binding protein in these assays. This is an assay-identity correction, not an inference from BCL2 membrane localization or an abstract naming a different gene.

Summary: The ubiquitination assay detects BCL2 as the modified substrate.

Reason: Full-text PMID:16717086 Figure 3G immunoprecipitates human BCL2 from reconstituted Bcl2-null fibroblasts in strong RIPA buffer, then probes the precipitate for ubiquitin; MG132 increases high-molecular-weight ubiquitin bands. The measured event is ubiquitination of BCL2. No BCL2 catalytic, scaffold or cofactor contribution to ubiquitin transfer is demonstrated. Remove this process assignment on the actual performer-versus-substrate distinction, not on a general assertion that BCL2 cannot regulate proteostasis.

Summary: BCL2 detected in cytoplasm (membrane-associated).

Reason: BCL2 is present in cytoplasm associated with membranes.

Summary: BCL2 is an integral membrane protein.

Reason: Well-supported - BCL2 has a C-terminal transmembrane anchor.

Summary: The cited study reports BCL2 interaction evidence involving BAG-1.

Reason: Preserve the interaction finding from PMID:9305631, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: BCL2 detected in nucleus in some studies.

Reason: Nuclear localization has been reported but is not the primary site of BCL2 function.

Summary: BCL2 detected in nucleus.

Reason: Secondary localization, not primary site of function.

Summary: BCL2 localizes to mitochondria.

Reason: Primary localization well-supported.

Summary: This PMID (36599) appears incorrect - refers to bacterial antibiotic resistance study.

Reason: PMID reference appears incorrect.

Summary: BCL2-dependent survival is a cellular response to the toxic stimulus in the cited experiments.

Reason: A response term does not require BCL2 to sense or chemically detoxify the toxicant. Its anti-apoptotic activity contributes to cellular resistance; retain this experimentally annotated context as non-core. The exact strength of causal evidence differs between the PP2A/phosphorylation intervention and the toxin-dependent Bax/BCL2-ratio study, so do not overstate direct toxin recognition.

Summary: BCL2 abundance changes during cytokine-regulated survival of activated human B cells.

Reason: PMID:9184696 reports stimulus- and timing-dependent changes in BCL2 expression with IL-10 and B-cell activation. The broad response annotation can describe adjustment of this survival effector; it does not assert cytokine recognition by BCL2. Retain the response context without claiming that expression correlations establish a unique BCL2-dependent mechanism.

Summary: Human BCL2 supports net expansion of early pre-B cells under defined growth conditions.

Reason: PMID:1373874 explicitly uses the human BCL2 gene in mouse pre-B cells. The approximately twofold net proliferative advantage occurs with IL-7 alone, whereas stromal coculture supports similar growth in controls. Retain the experimentally annotated non-core role in that context; the available evidence does not require or demonstrate faster cell-cycle progression.

Summary: BCL2 prevents apoptosis in early pre-B cells.

Reason: Core function demonstrated in B cell context.

Summary: BCL2 prevents apoptosis after T cell activation.

Reason: Core function in T cell context.

Summary: BCL2 anti-apoptotic function is evolutionarily conserved.

Reason: Core function with evolutionary conservation evidence.

Summary: BCL2 anti-apoptotic function demonstrated by mutant analysis.

Reason: Core function with mutant phenotype evidence.

Summary: BCL2 prevents apoptosis in endothelial cells.

Reason: Core function in endothelial cell context.

Summary: BCL2 protects bone marrow cells from chemotherapy-induced death.

Reason: Core anti-apoptotic function.

Summary: BCL2 protects neurons from apoptosis.

Reason: Core function in neuronal context.

Summary: BCL2 regulates ER-associated calcium fluxes through IP3 receptor interactions.

Reason: BCL2's calcium regulation function at the ER is documented but is secondary to its primary anti-apoptotic function at mitochondria.

Summary: BCL2 prevents apoptosis - core function.

Reason: Core function with experimental evidence.

Summary: BCL2 regulates the intrinsic apoptotic pathway in response to ER stress.

Reason: BCL2 at the ER can prevent ER stress-induced apoptosis, consistent with its anti-apoptotic function extending to ER stress responses.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:16790527 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: BCL2-dependent survival is a cellular response to the toxic stimulus in the cited experiments.

Reason: A response term does not require BCL2 to sense or chemically detoxify the toxicant. Its anti-apoptotic activity contributes to cellular resistance; retain this experimentally annotated context as non-core. The exact strength of causal evidence differs between the PP2A/phosphorylation intervention and the toxin-dependent Bax/BCL2-ratio study, so do not overstate direct toxin recognition.

Summary: The Vpr study establishes BCL2 protection but does not resolve the protease-binding annotation.

Reason: The full Methods and Results of PMID:10620603 assay Vpr interaction with ANT/VDAC, BCL2 inhibition of Vpr-induced mitochondrial changes, and reconstituted ANT/BAX/BCL2 membrane effects. Its discussion mentions HIV protease cleavage of BCL2 by citing a separate study. No specific BCL2/protease-binding measurement could be identified in this source. Leave the curated interaction unresolved pending its exact assay/source rather than infer that protection from a viral protein establishes protease binding.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:10837489 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:11054413 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: The cited study reports BCL2 interaction evidence involving RTN-XS.

Reason: Preserve the interaction finding from PMID:11126360, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The recorded interaction is not rejected, but its proposed BH3-specific interpretation is unresolved.

Reason: The available evidence from PMID:11278245 does not resolve the exact BCL2 partner/interface sufficiently to sustain the old automatic replacement by BH3 domain binding. Full-text retrieval was attempted; missing assay coverage is not evidence of paralog misattribution or absence of binding. Retain uncertainty pending inspection of the specific interaction experiment.

Summary: The reported interaction supports BH3-domain recognition by BCL2.

Reason: PMID:11463391 provides the partner-specific interaction context. For BECN1 and BAX interactions, independent direct domain-binding experiments in PMID:17446862 and PMID:9111042 establish the interface. The annotation is retained as the informative BH3-domain-binding function without inferring that all BCL2 partners use this surface. Preference among ligands is not absolute exclusion of lower-affinity binding.

Proposed replacements: BH3 domain binding

Summary: The cited study reports BCL2 interaction evidence involving BNIPL-2 and its BCH domain.

Reason: Preserve the interaction finding from PMID:12901880, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: The cited study reports BCL2 interaction evidence involving Nip1, Nip2 and Nip3.

Reason: Preserve the interaction finding from PMID:7954800, but remove the uninformative generic protein-binding label. This decision does not assert that the interaction is false. The source does not establish a BH3-domain-dependent molecular function for this particular partner merely because BCL2 also binds canonical BH3 ligands; no such replacement is inferred.

Summary: BCL2 detected in cytoplasm of placental cells.

Reason: Localization documented.

Summary: BCL2 localizes to mitochondria.

Reason: PMID:9027314 states: "Bcl-2 is an integral membrane protein located mainly on the outer membrane of mitochondria."

Summary: BCL2 localizes specifically to the OMM.

Reason: Direct experimental evidence from landmark paper.

Summary: BCL2 expression is documented in term placental cell populations.

Reason: PMID:11530860 is an immunolocalization study at term. Its distribution is compatible with a survival role, but placental expression alone provides weak support for the broad pregnancy process. Retain the over-annotation judgment on the source design, not on a claim that BCL2 cannot contribute to pregnancy.

Summary: BCL2 expression responds to signals released by irradiated cells.

Reason: PMID:15799693 measures BCL2 induction in unirradiated human keratinocytes exposed to irradiated-cell conditioned medium. This is a supported indirect radiation-response context, with a dose-dependent effect. The annotation does not assert that BCL2 detects radiation or repairs DNA.

Summary: Iron exposure increases BCL2 expression alongside enhanced endothelial-cell survival.

Reason: PMID:11264898 documents BCL2 induction after iron-salt treatment. The response annotation is retained as a contextual change in a survival effector; it does not imply iron binding, transport or metabolism by BCL2. The reported parallel expression and survival changes alone do not prove that BCL2 is the sole causal mediator.

Summary: BCL2 localizes to nuclear membrane in insect cells.

Reason: Nuclear envelope localization documented but not primary site.

Summary: BCL2 prevents intracellular acidification associated with apoptosis.

Reason: BCL2's effect on pH is part of its anti-apoptotic function, as cytoplasmic acidification occurs during apoptosis.

Summary: BCL2 executes nicotine-enhanced survival signaling through phosphorylation-dependent anti-apoptotic activity.

Reason: PMID:12421819 compares wild-type, phosphorylation-deficient S70A and phosphomimetic S70E BCL2. Nicotine-associated chemoprotection depends on a functional BCL2 phosphorylation site, so this is not merely an expression correlation or a passive modification. Retain the stimulus-response context as non-core.

Summary: BCL2 negatively regulates apoptosis.

Reason: Core function.

Summary: BCL2 prevents HIV-1 Vpr-induced apoptosis.

Reason: Core function demonstrated in viral infection context.

Summary: BCL2 forms heterodimers with BAX and other family members.

Reason: PMID:9111042 demonstrates heterodimerization: "Bcl-2 forms protein-protein homodimers with itself and heterodimers with Bax"

Summary: BCL2 binds BH3 domains from BAX, BAK, and BH3-only proteins through its hydrophobic groove.

Reason: This is a core molecular function of BCL2. PMID:9111042 demonstrates that BH3 peptides block BCL2 interactions.

Summary: BCL2 protects cells against the cytotoxic action of HIV-1 Vpr.

Reason: The live GO:0051607 definition includes protection of the cell or organism after a viral challenge; it does not require proof of reduced viral replication. Full-text PMID:10620603 shows that human BCL2 expression prevents Vpr-induced membrane-potential loss, phosphatidylserine exposure and DNA loss, with complementary reconstitution assays. This supports a contextual cellular defense response while leaving the consequences for viral spread unspecified.

Summary: BCL2 regulates neuronal apoptosis.

Reason: BCL2's anti-apoptotic function in neurons is well-documented.

Summary: The cited experiment establishes inhibition of mitochondrial cytochrome-c release.

Reason: In this source context, intact BCL2 prevents the measured mitochondrial changes and cytochrome-c efflux, so negative regulation is the more faithful specific term. This contextual replacement does not deny the separate proapoptotic converted-BCL2 state or use predominant antiapoptotic activity to refute the ancestral assertion globally.

Proposed replacements: negative regulation of release of cytochrome c from mitochondria

Summary: BCL2 regulates mitochondrial membrane permeability - core function.

Reason: Core function supported by sequence similarity evidence.

Summary: BCL2 helps maintain mitochondrial membrane potential.

Reason: Related to core anti-apoptotic function.

Summary: The cited experiment establishes inhibition of mitochondrial cytochrome-c release.

Reason: In this source context, intact BCL2 prevents the measured mitochondrial changes and cytochrome-c efflux, so negative regulation is the more faithful specific term. This contextual replacement does not deny the separate proapoptotic converted-BCL2 state or use predominant antiapoptotic activity to refute the ancestral assertion globally.

Proposed replacements: negative regulation of release of cytochrome c from mitochondria

Summary: BCL2 maintains B cell memory, supporting humoral immune response.

Reason: BCL2's role in B cell survival supports memory B cell maintenance, which is important for humoral immunity. This is a tissue-specific consequence of its anti-apoptotic function.

Summary: BCL2 prevents mitochondrial depolarization by preventing MOMP.

Reason: Core function - by preventing MOMP, BCL2 maintains membrane potential.